# Blujepa (gepotidacin mesylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gepotidacin

> The FDA approved Blujepa (gepotidacin mesylate), sponsored by GSK plc (GSK), on March 25, 2025 for to treat uncomplicated urinary tract infections.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Blujepa (gepotidacin mesylate) FDA approved?

Yes. The FDA approved Blujepa (gepotidacin mesylate), sponsored by GSK plc (GSK), on March 25, 2025 for to treat uncomplicated urinary tract infections. FDA novel drug approvals: "Blujepa | gepotidacin | 3/25/2025 | To treat uncomplicated urinary tract infectionsDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/gepotidacin)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/gepotidacin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Blujepa (gepotidacin mesylate) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | To treat uncomplicated urinary tract infections |
| Modality |  |
| FDA designations | priority review |

## Timeline

### March 25, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat uncomplicated urinary tract infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Blujepa | gepotidacin | 3/25/2025 | To treat uncomplicated urinary tract infectionsDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- openFDA Drugs@FDA: "NDA218230 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250325, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BLUJEPA (GEPOTIDACIN MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218230%22

### December 11, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218230 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251211, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BLUJEPA (GEPOTIDACIN MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218230%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gepotidacin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Blujepa (gepotidacin mesylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/gepotidacin

```bibtex
@misc{secapidev_pdufa_gepotidacin_20261116,
  title        = {Blujepa (gepotidacin mesylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gepotidacin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gepotidacin_20261116","title":"Blujepa (gepotidacin mesylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gepotidacin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
